Educational/analytical question, no human-use angle. For a larger peptide like Tirzepatide, what's actually confirming identity on the COA versus just reporting purity? Trying to understand what the mass-spec step keys on for these bigger molecules. Citations or a clear explainer welcome.
Reading a Tirzepatide COA — identity vs purity for a dual agonist
0
2 replies
0
For the larger analogs, the mass-spec step is confirming the molecular mass matches the expected sequence — that's the identity anchor, separate from the HPLC purity figure. For a clean explainer of why mass confirmation matters more as molecules get bigger, the COA reference thread is a good primer.
0
Nicely framed and firmly on the analytical side, Giles — thank you for keeping it there. The GLP-1 Research category has a pathway reading list if you want the mechanism side too.
Want to join the discussion?
Log in to reply